Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Cancer Control

Review

Suvranu Ganguli¹  Junsung Choi²  Nainesh S. Parikh²  Bela Kis²  Ghassan El-Haddad²  Rahul A. Sheth³  Paul B. Shyn⁴  Karen T. Brown⁵ 

[1] Center for Image Guided Cancer Therapy, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA;Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA;Department of Interventional Radiology, MD Anderson Cancer Center, Houston, TX, USA;Department of Radiology, Abdominal Imaging and Intervention, Brigham and Women’s, Boston, MA, USA;Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA;

关键词: hepatocellular carcinoma;    cholangiocarcinoma;    chemoembolization;    radioembolization;    percutaneous ablation;   

DOI  :  10.1177/1073274817729244

 received in 2017-12-13, accepted in 2017-04-14,  发布年份 2017

来源: Sage Journals

【 摘 要 】

Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC) are primary liver cancers where all or most of the tumor burden is usually confined to the liver. Therefore, locoregional liver-directed therapies can provide an opportunity to control intrahepatic disease with minimal systemic side effects. The English medical literature and clinical trials were reviewed to provide a synopsis on the available liver-directed percutaneous therapies for HCC and IHC. Locoregional liver-directed therapies provide survival benefit for patients with HCC and IHC compared to best medical treatment and have lower comorbid risks compared to surgical resection. These treatment options should be considered, especially in patients with unresectable disease.

【 授权许可】

CC BY-NC   
© The Author(s) 2017

【 图 表 】

Figure 1.